The case reported by Leussink and colleagues shows striking parallels with our previously described case of a delayed allergic reaction to natalizumab. We fully agree that we must anticipate additional cases of such delayed, type III systemic reactions to natalizumab in the future. The twopublished cases should help to raise awareness of this type of complication.
Correspondence: Dr Krumbholz, Institute for Clinical Neuroimmunology, Ludwig Maximilian University, Marchioninistraße 15, 81377 Munich, Germany (email@example.com).
Krumbholz M, Pellkofer H, Gold R, Hoffmann LA, Hohlfeld R, Kümpfel T. Type III Systemic Allergic Reaction to Natalizumab—Reply. Arch Neurol. 2008;65(6):849-852. doi:10.1001/archneur.65.6.852-a